一例芦可替尼成功救治免疫功能正常患者因巨细胞病毒感染导致嗜血细胞综合征的病例报告及文献回顾

耿芳芳; 杨美芳; 张璇; 赵宏; 周德; 胡建华

doi:10.1631/jzus.B2300232

Your Location：

Home >

Browse articles >

一例芦可替尼成功救治免疫功能正常患者因巨细胞病毒感染导致嗜血细胞综合征的病例报告及文献回顾

Scan for full text

文章被引用时，请邮件提醒。

Submit

Correspondence | Updated：2024-01-19

一例芦可替尼成功救治免疫功能正常患者因巨细胞病毒感染导致嗜血细胞综合征的病例报告及文献回顾
Typical hemophagocytic syndrome associated with cytomegalovirus infection in an immunocompetent patient: a case report and literature review
浙江大学学报（英文版）（B辑：生物医学和生物技术） 2023年24卷第12期页码：1159-1164
Affiliations：

1.State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Department of Infectious Diseases, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
2.Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
Funds：

the National Key Research and Development Program of China(2022YFC2304501)
DOI：10.1631/jzus.B2300232
中图分类号：
CSTR：

耿芳芳,杨美芳,张璇等.一例芦可替尼成功救治免疫功能正常患者因巨细胞病毒感染导致嗜血细胞综合征的病例报告及文献回顾[J].浙江大学学报（英文版）（B辑：生物医学和生物技术）,2023,24(12):1159-1164.

Fangfang GENG, Meifang YANG, Xuan ZHANG, et al. Typical hemophagocytic syndrome associated with cytomegalovirus infection in an immunocompetent patient: a case report and literature review[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2023,24(12):1159-1164.
耿芳芳,杨美芳,张璇等.一例芦可替尼成功救治免疫功能正常患者因巨细胞病毒感染导致嗜血细胞综合征的病例报告及文献回顾[J].浙江大学学报（英文版）（B辑：生物医学和生物技术）,2023,24(12):1159-1164. DOI： 10.1631/jzus.B2300232.

Fangfang GENG, Meifang YANG, Xuan ZHANG, et al. Typical hemophagocytic syndrome associated with cytomegalovirus infection in an immunocompetent patient: a case report and literature review[J]. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology), 2023,24(12):1159-1164. DOI： 10.1631/jzus.B2300232.

摘要

嗜血细胞综合征是一种罕见的因大量免疫细胞不受控制的激活和增殖以及细胞因子风暴引起的致命性疾病。尽管病毒感染是其常见病因，但由巨细胞病毒引起的嗜血细胞综合征较为少见。巨细胞病毒感染通常可在免疫功能低下或缺陷人群中引起系列疾病，而在免疫功能正常人群中多表现为无症状。本文报道了一例免疫功能正常患者感染巨细胞病毒引起嗜血细胞综合征后，经芦可替尼治疗成功好转。本文旨在强调免疫功能正常患者感染巨细胞病毒后可引起严重的嗜血细胞综合征，而及时给予芦可替尼治疗可以显著改善患者预后。同时，应进一步提高临床医师对免疫功能正常人群感染巨细胞病毒的重视，并为临床工作者提供新的诊疗思路。

Abstract

关键词

巨细胞病毒感染嗜血细胞综合征芦可替尼免疫功能正常

Keywords

references

Chen YH, Lee CH, Pei SN, 2015. Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis. Leuk Lymphoma, 56(5):1528-1529. https://doi.org/10.3109/10428194.2014.963082https://doi.org/10.3109/10428194.2014.963082

Das R, Guan P, Sprague L, et al., 2016. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood, 127(13):1666-1675. https://doi.org/10.1182/blood-2015-12-684399https://doi.org/10.1182/blood-2015-12-684399

Dioverti MV, Razonable RR, 2016. Cytomegalovirus. Microbiol Spectr, 4:4. https://doi.org/10.1128/microbiolspec.DMIH2-0022-2015https://doi.org/10.1128/microbiolspec.DMIH2-0022-2015

Gao ZR, Ling XY, Shi CY, et al., 2022. Tumor immune checkpoints and their associated inhibitors. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(10):823-843. https://doi.org/10.1631/jzus.B2200195https://doi.org/10.1631/jzus.B2200195

Harrison C, Kiladjian JJ, Al-Ali HK, et al., 2012. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med, 366(9):787-798. https://doi.org/10.1056/NEJMoa1110556https://doi.org/10.1056/NEJMoa1110556

He K, Xu SS, Shen LJ, et al., 2022. Ruxolitinib as adjunctive therapy for hemophagocytic lymphohistiocytosis after liver transplantation: a case report and literature review. J Clin Med, 11(21):6308. https://doi.org/10.3390/jcm11216308https://doi.org/10.3390/jcm11216308

Heine A, Held SA, Daecke SN, et al., 2013. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood, 122(7):1192-1202. https://doi.org/10.1182/blood-2013-03-484642https://doi.org/10.1182/blood-2013-03-484642

Keenan C, Nichols KE, Albeituni S, 2021. Use of the JAK inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis. Front Immunol, 12:614704. https://doi.org/10.3389/fimmu.2021.614704https://doi.org/10.3389/fimmu.2021.614704

Meng GQ, Wang JS, Wang YN, et al., 2021. Successful treatment of cytomegalovirus-induced hemophagocytic lymphohistiocytosis with ruxolitinib as a first-line treatment. Infect Dis Now, 51(3):311-313. https://doi.org/10.1016/j.idnow.2020.10.010https://doi.org/10.1016/j.idnow.2020.10.010

Parampalli Yajnanarayana S, Stübig T, Cornez I, et al., 2015. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. Br J Haematol, 169(6):824-833. https://doi.org/10.1111/bjh.13373https://doi.org/10.1111/bjh.13373

Rafailidis PI, Mourtzoukou EG, Varbobitis IC, et al., 2008. Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review. Virol J, 5:47. https://doi.org/10.1186/1743-422X-5-47https://doi.org/10.1186/1743-422X-5-47

Risitano AM, Peffault de Latour R, 2020. Ruxolitinib for steroid-resistant acute GVHD. Blood, 135(20):1721-1722. https://doi.org/10.1182/blood.2020005364https://doi.org/10.1182/blood.2020005364

Sepulveda FE, de Saint Basile G, 2017. Hemophagocytic syndrome: primary forms and predisposing conditions. Curr Opin Immunol, 49:20-26. https://doi.org/10.1016/j.coi.2017.08.004https://doi.org/10.1016/j.coi.2017.08.004

Shen CH, Hwang CE, Chen YY, et al., 2014. Hepatitis B virus reactivation associated with ruxolitinib. Ann Hematol, 93(6):1075-1076. https://doi.org/10.1007/s00277-013-1936-5https://doi.org/10.1007/s00277-013-1936-5

Sridhar S, Chung TWH, Chan JFW, et al., 2018. Emergence of cytomegalovirus mononucleosis syndrome among young adults in Hong Kong linked to falling seroprevalence: results of a 14-year seroepidemiological study. Open Forum Infect Dis, 5(10):ofy262. https://doi.org/10.1093/ofid/ofy262https://doi.org/10.1093/ofid/ofy262

Tong LX, Jackson J, Kerstetter J, et al., 2014. Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment. J Am Acad Dermatol, 70(3):‍e59-e60. https://doi.org/10.1016/j.jaad.2013.09.035https://doi.org/10.1016/j.jaad.2013.09.035

Vannucchi AM, 2015. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med, 372(17):1670-1671. https://doi.org/10.1056/NEJMc1502524https://doi.org/10.1056/NEJMc1502524

Wang X, Dai CY, Yin YF, et al., 2021. Blocking the JAK2/STAT3 and ERK pathways suppresses the proliferation of gastrointestinal cancers by inducing apoptosis. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 22(6):492-503. https://doi.org/10.1631/jzus.B2000842https://doi.org/10.1631/jzus.B2000842

浏览量

Downloads

CSCD

工具集

关联资源

暂无数据